This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Bacterial Infections  • Malaria  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2004;292:2703-2704.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The largest malaria vaccine efficacy trial ever conducted in Africa has proven that a candidate vaccine is safe in children aged 1 to 4 years and can protect a significant proportion of them against uncomplicated malaria, infection, and severe forms of the disease for at least 6 months.

"This is clearly the best result we’ve ever seen with a candidate malaria vaccine," said Pedro Alonso, MD, PhD, principal investigator of the study and head of the Center for International Health of the Hospital Clinic at the University of Barcelona, in Spain. "All the results point in the same direction with great consistency and substantial precision. So we’re quite certain not only that the vaccine has been safe and immunogenic but that we’ve seen clear efficacy of this vaccine."

The double-blind, randomized controlled phase 2 trial conducted by Alonso and colleagues involved 2022 children in southern Mozambique (. . . [Full Text of this Article]

TRIAL RESULTS